Trials / Conditions / Solid Tumor Malignancy

Solid Tumor Malignancy

12 registered clinical trials studyying Solid Tumor Malignancy — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Withdrawn	Pilot Study Evaluating Tumor Microenvironment Interaction in Solid Tumor Patients NCT06922825	Eben Rosenthal	EARLY_Phase 1
Recruiting	Safety Trial of 68Ga/177Lu-NRT6020 in FAP-Positive Advanced Solid Tumor Patients NCT06911489	Chengdu New Radiomedicine Technology Co. LTD.	Phase 1
Recruiting	A Clinical Trial of SIBP-A18 Injection in the Treatment of Advanced Malignant Solid Tumor Patients NCT06985368	Shanghai Institute Of Biological Products	Phase 1
Not Yet Recruiting	Clinical Application of 99mTc-FDPH46 SPECT/CT Imaging in Malignant Solid Tumor: a Prospective Exploratory Stud NCT06753513	Zhejiang University	—
Terminated	A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metasta NCT06630247	Exelixis	Phase 1
Recruiting	A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product NCT05768269	Century Therapeutics, Inc.	—
Recruiting	HLA-A*02:01 Allele Frequency and the NY-ESO-1 Expression Status in Cancer Patients in Taiwan NCT06665776	PharmaEssentia	—
Completed	Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipi NCT05164016	St. Jude Children's Research Hospital	—
Completed	A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic NCT04847050	National Cancer Institute (NCI)	Phase 2
Terminated	Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectabl NCT03822117	Incyte Corporation	Phase 2
Withdrawn	Selinexor Combination Ph 1 Study NCT05177276	Martin Gutierrez	Phase 1 / Phase 2
Completed	Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas NCT00647764	Esanex Inc.	Phase 1